United Kingdom · 
Who invested in Docbot Labs?
Docbot Labs's investors include Ascension, Frontline Ventures and Concept Ventures.
2023
$528KPre-seed$660KPre-seedUnited Kingdom · Pre-seed startup
Who invested in Docbot Labs
2 rounds we have observed, with the 3 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$1.2Mraised across 2 rounds since 2022, from 2 sources
$528KPre-seed$660KPre-seed
- Latest round
- Pre-seed, $660KNov 2022
- Step-upi
- 1.2×
- Investors
- 3
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Pre-seed, $528K Jun 2022
- Biggest round
- $660K Pre-seed · Nov 2022
- Between rounds
- 5 months from the last two
The rounds
- Nov 2022
- Jun 2022Pre-seed$528K
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet
Who was in which round
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Quick answers about Docbot Labs
How much has Docbot Labs raised?
Docbot Labs has raised $1.2M across 2 rounds since 2022.
When did Docbot Labs last raise?
Docbot Labs's most recent round was a Pre-seed of $660K in Nov 2022.
What was Docbot Labs's biggest round?
Its most recent round, $660K in Nov 2022, is also its largest on record.
Who backed Docbot Labs first?
Docbot Labs's first round on record, in Nov 2022, was backed by Ascension, Frontline Ventures and Concept Ventures.
What stage is Docbot Labs at?
Docbot Labs's latest named round is a Pre-seed, in Nov 2022.
Where is Docbot Labs based?
Docbot Labs is based in the United Kingdom.
Companies like Docbot Labs
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.